US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Generate Biomedicines

15.72

+0.33002.14%

Post-market: 15.770.0500+0.32%18:26 EDT

Volume:666.04K

Turnover:10.47M

Market Cap:2.02B

PE:-4.80

High:15.88

Open:15.44

Low:15.32

Close:15.39

52wk High:22.67

52wk Low:11.00

Shares:128.19M

Float Shares:60.29M

Volume Ratio:0.67

T/O Rate:1.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2762

EPS(LYR):-4.9816

ROE:-81.72%

ROA:-34.63%

PB:4.42

PE(LYR):-3.16

Loading ...

Overview Company News Filings

Generate Biomedicines publishes corporate presentation on programmable biology drug design platform

BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug

Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Generate Biomedicines Initiated at Overweight by Piper Sandler

Generate Biomedicines Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Price Target $20

THOMSON REUTERS

Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating

MT Newswires Live

Generate Biomedicines Initiated at Buy by Guggenheim

Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target

MT Newswires Live

Generate Biomedicines initiated with a Buy at Guggenheim

Generate Biomedicines initiated with an Overweight at Piper Sandler

Generate Biomedicines initiated with a Buy at Goldman Sachs

Generate Biomedicines Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $24

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/GENB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GENB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","market":"US","secType":"STK","nameCN":"Generate Biomedicines","latestPrice":15.72,"timestamp":1789156800000,"preClose":15.39,"halted":0,"volume":666037,"hourTrading":{"tag":"盘后","latestPrice":15.77,"preClose":15.72,"latestTime":"18:26 EDT","volume":8837,"amount":138935.950264,"timestamp":1789165572541,"change":0.05,"changeRate":0.003181,"amplitude":0.014631},"delay":0,"changeRate":0.021442495126705655,"floatShares":60288200,"shares":128192484,"eps":-3.27625,"marketStatus":"Post-Mkt","change":0.33,"latestTime":"09-11 18:35:16 EDT","open":15.44,"high":15.875,"low":15.32,"amount":10467542.725846,"amplitude":0.036062,"askPrice":15.9,"askSize":2,"bidPrice":15.4,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-3.27625,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789171200000},"marketStatusCode":4,"adr":0,"listingDate":1772168400000,"exchange":"NASDAQ","adjPreClose":15.39,"preHourTrading":{"tag":"盘前","latestPrice":15.46,"preClose":15.39,"latestTime":"09:29 EDT","volume":3507,"amount":54482.977458,"timestamp":1789133399999,"change":0.07,"changeRate":0.004548,"amplitude":0.051917},"postHourTrading":{"tag":"盘后","latestPrice":15.77,"preClose":15.72,"latestTime":"18:26 EDT","volume":8837,"amount":138935.950264,"timestamp":1789165572541,"change":0.05,"changeRate":0.003181,"amplitude":0.014631},"volumeRatio":0.674306},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","floatShares":60288200,"roa":"-34.63%","roe":"-81.72%","lyrEps":-4.981642,"volumeRatio":0.674306,"shares":128192484,"dividePrice":0,"high":15.875,"amplitude":0.036062,"preClose":15.39,"low":15.32,"week52Low":11,"pbRate":"4.42","psRate":"76.09","week52High":22.6699,"institutionHeld":0,"latestPrice":15.72,"committee":0.2,"eps":-3.27625,"divideRate":0,"volume":666037,"delay":0,"ttmEps":-3.27625,"open":15.44,"prevYearClose":16,"prevWeekClose":16.39,"prevMonthClose":15.27,"prevQuarterClose":16.87,"fiveDayClose":16.34,"twentyDayClose":15.03,"sixtyDayClose":13.37},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GENB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"GENB","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2026-05-07","symbol":"GENB","fiscalQuarterEnding":"2026/03","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GENB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GENB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1782360000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GENB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GENB","date":"2026-09-10","current":-4.798169,"percent":0.293233,"low":-11.002825,"twenty":-8.743953,"median":-8.030177,"eighty":-7.546252,"high":-6.883628,"avg":-8.175845,"sd":0.73871,"marketCap":1992029806},"quantilePoints":[{"date":"2026-02-27","current":-10.037721,"twenty":-10.037721,"median":-10.037721,"eighty":-10.037721,"marketCap":2039203216},{"date":"2026-03-06","current":-7.810602,"twenty":-7.936073,"median":-7.722772,"eighty":-7.484376,"marketCap":1586755002},{"date":"2026-03-13","current":-8.331309,"twenty":-7.979988,"median":-7.660036,"eighty":-7.484376,"marketCap":1692538669},{"date":"2026-03-20","current":-7.710225,"twenty":-7.979988,"median":-7.68513,"eighty":-7.484376,"marketCap":1566362970},{"date":"2026-03-27","current":-8.061545,"twenty":-7.979988,"median":-7.697677,"eighty":-7.484376,"marketCap":1637735082},{"date":"2026-04-02","current":-8.350129,"twenty":-7.996299,"median":-7.697677,"eighty":-7.419131,"marketCap":1696362175},{"date":"2026-04-10","current":-7.233433,"twenty":-7.996299,"median":-7.647489,"eighty":-7.419131,"marketCap":1469500817},{"date":"2026-04-17","current":-7.910979,"twenty":-8.036451,"median":-7.697677,"eighty":-7.419131,"marketCap":1607147034},{"date":"2026-04-24","current":-8.067818,"twenty":-8.0628,"median":-7.732183,"eighty":-7.42164,"marketCap":1639009584},{"date":"2026-05-01","current":-7.923526,"twenty":-8.036451,"median":-7.810602,"eighty":-7.471829,"marketCap":1609696038},{"date":"2026-05-08","current":-8.522653,"twenty":-8.180743,"median":-7.816876,"eighty":-7.489394,"marketCap":1731410980},{"date":"2026-05-15","current":-8.844872,"twenty":-8.266063,"median":-7.84197,"eighty":-7.500687,"marketCap":1971654609},{"date":"2026-05-22","current":-8.039526,"twenty":-8.266063,"median":-7.83256,"eighty":-7.486839,"marketCap":1792130926},{"date":"2026-05-29","current":-7.527711,"twenty":-8.282375,"median":-7.816876,"eighty":-7.489371,"marketCap":1678039615},{"date":"2026-06-05","current":-8.453579,"twenty":-8.282375,"median":-7.810602,"eighty":-7.474106,"marketCap":1884429514},{"date":"2026-06-12","current":-7.435699,"twenty":-8.229473,"median":-7.788352,"eighty":-7.435629,"marketCap":1657528818},{"date":"2026-06-18","current":-7.976268,"twenty":-8.211907,"median":-7.788092,"eighty":-7.435594,"marketCap":1778029753},{"date":"2026-06-26","current":-9.442705,"twenty":-8.343203,"median":-7.810602,"eighty":-7.4449,"marketCap":2104920587},{"date":"2026-07-02","current":-9.488711,"twenty":-8.508838,"median":-7.810602,"eighty":-7.463837,"marketCap":2115175986},{"date":"2026-07-10","current":-9.040154,"twenty":-8.869967,"median":-7.84197,"eighty":-7.484992,"marketCap":2015185848},{"date":"2026-07-17","current":-7.855502,"twenty":-8.85402,"median":-7.855502,"eighty":-7.488094,"marketCap":1751109331},{"date":"2026-07-24","current":-7.953265,"twenty":-8.801131,"median":-7.883241,"eighty":-7.493159,"marketCap":1772902053},{"date":"2026-07-31","current":-8.06828,"twenty":-8.626167,"median":-7.861253,"eighty":-7.503197,"marketCap":1798540550},{"date":"2026-08-07","current":-7.489636,"twenty":-8.522653,"median":-7.910979,"eighty":-7.503197,"marketCap":1780593602},{"date":"2026-08-14","current":-8.114449,"twenty":-8.453579,"median":-7.917253,"eighty":-7.52196,"marketCap":1929137113},{"date":"2026-08-21","current":-8.632737,"twenty":-8.626167,"median":-7.947085,"eighty":-7.52196,"marketCap":2052355451},{"date":"2026-08-28","current":-8.513962,"twenty":-8.702922,"median":-7.964766,"eighty":-7.527711,"marketCap":2024117915},{"date":"2026-09-04","current":-8.821696,"twenty":-8.713719,"median":-7.99352,"eighty":-7.544963,"marketCap":2097278804},{"date":"2026-09-10","current":-8.378991,"twenty":-8.743953,"median":-8.030177,"eighty":-7.546252,"marketCap":1992029806}],"updateTime":1789166116523},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GENB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625494368","title":"Generate Biomedicines publishes corporate presentation on programmable biology drug design platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2625494368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625494368?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:07","pubTimestamp":1775646420,"startTime":"0","endTime":"0","summary":"Generate Biomedicines outlined strategy to use generative biology and scaled lab automation to lower drug-discovery time to proof of concept to 3-5 years from 6-8 years.Company also projected cost to proof of concept of $25-60 million versus $380 million for traditional discovery.Lead program GB-0895, anti-TSLP monoclonal antibody, is positioned for twice-yearly dosing with reported human half-life of 98 days.GB-0895 is in Phase 3 development in severe asthma, with Phase 1b results in moderate-to-severe COPD slated for 1H 2026.Pipeline catalyst slate includes planned Phase 1 first-patient-dosed starts in 1H 2026 for GB-4362, an MMAE toxin neutralizer, in first-line metastatic urothelial cancer, alongside GB-5267 MUC-16 armored CAR-T in relapsed or refractory platinum-resistant ovarian cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL1MDjP1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622006872","title":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2622006872","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622006872?lang=en_us&edition=fundamental","pubTime":"2026-03-26 01:52","pubTimestamp":1774461124,"startTime":"0","endTime":"0","summary":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug** Morgan Stanley initiates drug developer Generate Biomedicines GENB.O with an \"overweight\" rating as research quiet period ends** Company secured a valuation of nearly $1.91 bln at open after its debut on the Nasdaq late last month** Brokerage cites, \"we see GENB's lead asset, GB-0895, as having best-in-class potential vs. blockbuster generating commercial benchmarks\"** GB-0895 is GENB's lead product to treat severe asthma which is being tested in a late-stage trial ** \"We believe GB-0895 has credible best-in-class potential in severe asthma by improving on a validated mechanism rather than reinventing the biology\"- MS** Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities and Cantor were the underwriters for GENB's offering** As of last close, stock down 24% since its debut on Feb. 27  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D1S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB","PIPR","BK4127","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077173","title":"Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077173","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077173?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:45","pubTimestamp":1774449917,"startTime":"0","endTime":"0","summary":"Salveen Richter, an analyst from Goldman Sachs, has initiated a new Buy rating on Generate Biomedicines, Inc. (GENB). Salveen Richter has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/generate-biomedicines-differentiated-ai-driven-protein-platform-with-gb-0895-asthma-lead-and-emerging-oncology-upside-justifies-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/generate-biomedicines-differentiated-ai-driven-protein-platform-with-gb-0895-asthma-lead-and-emerging-oncology-upside-justifies-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIX","CHAT","AIPO","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622023931","title":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023931?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425680,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador ResourcesMarch 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wedn","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","AVAH","DINO","FIGG","HAL","AIR","AMZN","FIG","DK","FANG","DG","CVX","BP","GENB","KBH","BCAX","BPH","BZAI","CNM","BRZE","CVI","HD","CDE","FRPT","ABSI","BXP","AZYY","INSM","GLW","AARD","BAM","EVGO","CEG","BWXT","CEGX","USAW.SI","AMZD","APEI","ESE","MTDR","ARE","AMZU","ACAD","AVTX","CALM","AFG","ADUS","AMZP","BTM"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621706775","title":"Generate Biomedicines Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706775?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:02","pubTimestamp":1774357320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 09:02 ET (13:02 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621205062","title":"Generate Biomedicines Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Price Target $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2621205062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621205062?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:44","pubTimestamp":1774356269,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0T1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061288","title":"Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061288","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061288?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:50","pubTimestamp":1774353049,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061159","title":"Generate Biomedicines Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061159?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:46","pubTimestamp":1774352760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 07:46 ET (11:46 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063010","title":"Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063010","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063010?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:17","pubTimestamp":1774347431,"startTime":"0","endTime":"0","summary":"Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621068889","title":"Generate Biomedicines initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621068889?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:15","pubTimestamp":1774343742,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $30 price target The firm has “high conviction in multi-blockbu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621050714","title":"Generate Biomedicines initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621050714?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:00","pubTimestamp":1774342831,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff initiated coverage of Generate Biomedicines (GENB) with an Overweight rating and $24 price target The company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621575470","title":"Generate Biomedicines initiated with a Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2621575470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621575470?lang=en_us&edition=fundamental","pubTime":"2026-03-24 16:35","pubTimestamp":1774341311,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $26 price target The company integrates generative AI models...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4543","LU2237438978.USD","BK4550","LU2237443622.USD","BK4139","BK4587","LU0345770993.USD","LU0061475181.USD","LU2237443465.HKD","LU2750360997.AUD","LU1868836914.USD","LU2471134952.CNY","LU2471134796.USD","LU1868837300.USD","LU1868836757.USD","LU1894683348.USD","BK4127","GSX","BK4588","BK4528","BK4504","BK4023","GENB","LU2237443895.HKD","LU1668664300.SGD","IE00B19Z3581.USD","LU0742534661.SGD","IE0034235188.USD","LU2750360641.GBP","BK4585","LU2471134523.USD","AI","IE00BSNM7G36.USD","BK4551","IE0004086264.USD","LU1791807156.HKD","IE00B19Z3B42.SGD","LU1868836591.USD","LU0251131958.USD","LU2237443382.USD","AIYY","LU0345770308.USD","LU0106831901.USD","IE0004091025.USD","LU2237443978.SGD","IE0002270589.USD","LU2471134879.HKD","BK4516","LU2265009873.SGD","LU0251142724.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621000051","title":"Generate Biomedicines Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2621000051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621000051?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:43","pubTimestamp":1774338190,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40B0RB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621012051","title":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco","url":"https://stock-news.laohu8.com/highlight/detail?id=2621012051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621012051?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:39","pubTimestamp":1774337945,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, SunocoMarch 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apogee","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL4N40C0IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMCI","DXCM","BK4165","CF","BK4504","BK4515","RLMD","SMCL","BK4189","INSM","VTRS","APGE","PFE","SRZN","LU0690374961.EUR","SMCC","WEC","NYT","CCL","LGND","T","LU0354030511.USD","SUN","LW","LU0496365809.HKD","RL","BRX","APA","FRT","NCNO","TSN","KMI","SMCX","VZ","ACDC","ADM","SPG","BG","REG","STRO","XNCR","GENB","SMCY","CXW","DAR","SMYY","MKC","KRYS","SMCZ","ECL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":54,"code":"91000000","status":"200"}]}}